다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (ESPR) 뉴스

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ESPR

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/29	05:16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/25	05:18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/25	05:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/25	05:13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/23	22:00	GlobeNewswire Inc.	Esperion to Participate in Upcoming June Investor Conferences	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/22	21:00	GlobeNewswire Inc.	First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/21	05:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/20	19:00	GlobeNewswire Inc.	Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/18	04:08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/14	21:00	GlobeNewswire Inc.	Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/11	05:00	GlobeNewswire Inc.	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/09	05:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	21:50	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	20:29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/05/07	19:00	GlobeNewswire Inc.	Esperion Reports First Quarter 2024 Financial Results	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/29	21:00	GlobeNewswire Inc.	Esperion to Participate in Upcoming May Investor Conferences	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/23	21:00	GlobeNewswire Inc.	Esperion to Report First Quarter 2024 Financial Results on May 7	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/08	03:45	GlobeNewswire Inc.	Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/04/01	21:00	GlobeNewswire Inc.	Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/26	21:00	GlobeNewswire Inc.	Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/26	05:00	GlobeNewswire Inc.	Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	07:26	Business Wire	U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	04:10	GlobeNewswire Inc.	U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/03/23	00:04	GlobeNewswire Inc.	CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	23:19	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	21:23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/27	20:00	GlobeNewswire Inc.	Esperion Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/17	06:30	GlobeNewswire Inc.	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/15	04:14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc
2024/02/15	00:50	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ESPR	Esperion Therapeutics Inc

검색 관련기사 보기:NASDAQ:ESPR

1 2 3 4 5 6 7 8 9 10 다음 >>

Energy Select Sector SPDR

Health Care Select Sector

JP Morgan Chase

BNP Paribas (QX)

Verizon Communications

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관